Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 13/20 | 0.62 |
| ▸ | MMP8 | P22894 | 8/20 | 0.62 |
| ▸ | MMP1 | P03956 | 11/20 | 0.60 |
| ▸ | MMP2 | P08253 | 11/20 | 0.60 |
| ▸ | MMP3 | P08254 | 11/20 | 0.60 |
| ▸ | MMP7 | P09237 | 9/20 | 0.60 |
| ▸ | MMP9 | P14780 | 8/20 | 0.60 |
| ▸ | BMP1 | P13497 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808879 | 0.94 | MMP13 (0.58) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL6918801 | 0.92 | MMP13 (0.57) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL6290473 | 0.91 | MMP13 (0.65) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL7046221 | 0.90 | MMP13 (0.58) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL6290466 | 0.85 | MMP13 (0.69) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL6291020 | 0.84 | MMP13 (0.84) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL6810494 | 0.81 | MMP13 (0.59) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL7043145 | 0.81 | MMP13 (0.72) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL6804554 | 0.80 | MMP13 (0.64) | MMP13MMP8MMP1MMP2MMP3 | |
| SCHEMBL7347776 | 0.79 | MMP13 (0.54) | MMP13MMP8MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949545-B2 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-27 | — | — | US | claimed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
| US-6949545-B2 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-07-01 | — | — | US | disclosed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | disclosed |
| EP-1265864-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070691-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP8 37/4885MMP1 15/4885 |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP8 37/4885MMP1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.